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background: salvage radiotherapy (srT) is the main potentially curative treatment after biochemical failure/locoregional 
relapse post-radical prostatectomy (rp). The aim of the study was to characterize the population who underwent srT after rp 
at our Department, to understand the influence of several potential prognosis factors, and to determine possible optimiza-
tion strategies.
Materials and methods: We retrospectively analyzed patients undergoing srT at our department between 2012 and 2017, 
evaluating patient, tumor and treatment characteristics, restaging procedures and clinical outcomes — namely biochemi-
cal relapse-free survival (Bc-rFs), clinical relapse-free survival (c-rFs), additional hormone therapy-free survival (hT-Fs) and 
overall survival (Os). We assessed potential prognostic factors by univariate and multivariate models (MVa).
results: We included 277 patients (median age 68 years). Median pre-srT psa was > 0.5ng/mL in 54.9%. all underwent 
prostate bed irradiation. pelvic lymph nodes were included in 9.7%. Outcome analysis was performed for 264 patients (35.6 
months median follow-up).  at 3 years, Bc-rFs was 61.4%, c-rFs was 81.3%, hT-Fs was 79.9% and Os was 96.6%. Most relapses 
occurred in regional lymph nodes only (47.9% patients who relapsed). On MVa, lymphovascular invasion, advanced pT-stages 
and negative margins negatively influenced Bc-rFs (p = 0.029, p = 0.002 and p < 0.001) and hT-Fs (p = 0.001, p = 0.029 and 
p = 0.002). c-rFs was worsened by lymphovascular invasion (p = 0.009) and negative margins (p = 0.015). These had no effect 
on Os. Bc-rFs and hT-Fs were improved when srT started while psa ≤ 0.5 ng/mL (p < 0.05).
conclusion: Lymphovascular invasion, higher pT-stages and negative margins negatively affected prognosis. an early start of 
srT (psa ≤ 0.5 ng/mL) predicted better Bc-rFs and hT-Fs.
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Introduction
Salvage radiotherapy (sRT) is a potentially cura-
tive treatment for patients with prostatic bed and/or 
nodal relapse without distant metastasis after radi-
cal prostatectomy (RP). Several factors have been 
associated with a worse prognosis in this setting, 
both related to initial disease characteristics and 
to the relapse itself (such as PSA). Understand-
ing the influence of these factors may contribute 
to an improvement in patient selection, restaging 
procedures, sRT timing, sRT technical factors, and 
surveillance of this particular cohort [1, 2]. Also, 
recent prospective studies, namely RADICALS-RT, 
RAVES and GETUG-AFU 17 [3–5] suggest that 
adjuvant radiotherapy may not be advantageous for 
most patients when compared to an early salvage 
strategy. Hence, identifying prognosis factors may 
aid in selecting patients for whom this approach 
can be confidently proposed.
Our purpose was, therefore, to characterize the 
population who had undergone sRT for relapse af-
ter radical prostatectomy (RP) at our Department, 
to report clinical outcomes, patterns of relapse and 
prognostic factors, and to determine potential op-
timization strategies. We also aimed to understand 
the impact of an early start of sRT after relapse.
Materials and methods
We performed a retrospective analysis of all pa-
tients who had received salvage radiotherapy for 
biochemical/clinical relapse after RP for prostate 
cancer at our Department. Information was ob-
tained from clinical records regarding initial disease 
characteristics and primary treatment, restaging af-
ter biochemical relapse (including PSA and imag-
ing studies), treatment after relapse (radiotherapy 
and hormone therapy) and follow-up (namely ra-
diotherapy side effects, total PSA measurements, 
imaging studies, further treatments received). We 
included all patients who suffered a biochemical 
relapse after RP for prostate cancer (defined by a se-
rum PSA ≥ 0.2 ng/mL followed by a second confir-
matory level, as per ASTRO/AUA and EAU criteria 
[6]). After performing the restaging procedures 
(MRI, PET/CT and/or bone scintigraphy, which 
are further explored in the Results section) and be-
ing discussed at a multidisciplinary tumor board, 
the patients were referenced to our Department for 
sRT and treated between 1st January 2012 and 31st 
December 2017. Since the sRT treatment character-
istics were not uniform for all patients (total dose 
and fractionation, type of boost, treatment vol-
umes, technique), they are analysed in the Results 
section. We considered the following organs at risk 
relevant for planning purposes: rectum (V60 < 35% 
and V50 < 50%), bladder (maximum dose < 65 Gy, 
V65 < 50%), femoral heads (V52 < 100%) and pe-
nile-bulb (not dose-limiting, to a medium dose < 50 
Gy or D90 < 50 Gy). Patients were initially staged 
according to the AJCC 7th edition. Early sRT was 
defined as sRT starting with a PSA ≤ 0.5 ng/mL.
Follow-up and toxicity evaluation
After sRT, patients remained in follow-up, un-
dergoing periodical serum PSA measurements 
and clinical evaluation for relapse and side effect 
monitoring, at physician discretion. Biochemical 
relapse after sRT was defined as a rise in serum 
PSA ≥ 0.2 ng/mL above the nadir followed by an 
equal or higher value [7], or as an absence of serum 
PSA nadir [8]. For patients under salvage andro-
gen deprivation therapy (ADT), PSA values were 
included from the moment of ADT suspension. 
Clinical recurrence was assessed by physical exami-
nation, computed tomography (CT), 68Ga-PSMA 
PET/CT positron emission tomography/computed 
tomography (PET/CT), 18F-choline PET/CT and/or 
bone scintigraphy after biochemical recurrence.
Data collection and analysis
Data was collected from clinical records, stored 
and analyzed using IBM SPSS Statistics Version 25. 
We evaluated the following outcomes: biochemical 
relapse-free survival (BC-RFS; time from the end 
of sRT to the date of biochemical relapse), clinical 
relapse-free survival (C-RFS; time from the end 
of sRT to the date of clinical relapse, determined 
by physical examination or imaging studies); addi-
tional hormone therapy-free survival (HT-FS; time 
from end of sRT to the first day of further hormone 
therapy) and overall survival (OS; time from end 
of sRT to death). The Kaplan-Meier estimator was 
used to build survival curves, and survival between 
groups was compared with the Log-Rank test. Uni-
variate models were built to assess the influence of 
each disease characteristic on the outcome (includ-
ing the following: grade group, perineural invasion, 
lymphovascular invasion, surgical margin, pT stage, 
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initial PSA, presence of undetectable post-RP PSA, 
and time between RP and relapse). Then, multi-
variate models retaining significant variables were 
built to determine the influence of each of them 
on the prognosis, and hazard ratios were obtained 
by Cox proportional hazards regression models. 
The Mann-Whitney test was used to compare PSA 
values between groups, and the relationship be-
tween qualitative variables was determined with 
the Chi-Square test. For a more simple description 
of the results, patients were divided into two groups 
according to pre-sRT PSA: group A (≤ 0.5 ng/mL) 
and group B (> 0.5 ng/mL).
results
We included 277 patients who were treated at our 
department from 2012 to 2017, with a median age 
of 68 years (48 to 81 years). Disease and primary 
treatment characteristics are presented in Table 1.
primary treatment
Most patients underwent RP at other hospitals 
(with only 30.3% having been primarily treated 
at our institution). Median pre-RP PSA was 8.2 
ng/mL and median post-RP PSA was 0.03 ng/mL. 
Primary tumor was described as Gleason ≤ 7 for 
most patients (n = 208, 75.1%), and the major-
ity for whom the information was available had 
perineural invasion (n = 169, 61.0%) and did not 
have lymphovascular invasion (reported in 42 pa-
tients, 15.2%). Patients were initially staged as pT2a 
(8.7%), pT2b (4.3%), pT2c (43.3%), pT3a (30.3%) 
or pT3b (11.9%). Most (75.8%) did not undergo 
pelvic lymphadenectomy. Out of the 67 patients 
who did, a median of 6 lymph nodes were excised, 
and 4 patients had nodal disease. Positive margins 
were described for 67 surgical specimens (24.2%). 
Most patients did not receive adjuvant hormone 
therapy (n = 257, 92.7%) after radical prostatec-
tomy. Median time from RP to biochemical relapse 
was 30 months (range: 1–184) and median time 
from diagnosis of relapse and start of sRT was 9.6 
months (range: 0.23–135.7).
restaging procedures
Median pre-sRT PSA was 0.59 (IQR 0.77; mini-
mum PSA was 0.137 for patients who were not 
on ADT). Pre-sRT PSA was > 0.5 ng/mL for 152 
patients (54.9%). As shown on Figure 1, pelvic 
magnetic resonance image (MRI) was requested 
for 206 patients (74.4%) prior to sRT, having iden-
tified prostate bed relapse on 44.7% and additional 
pelvic nodal relapse on 1.9%. PET/CT imaging was 
performed on 72 patients: 68Ga-PSMA PET/CT on 
51 (18.4%), 18F-choline PET/CT on 22 (7.9%) and 
both on 1 patient.
Out of the 92 patients whose MRI was negative, 
24 (26.1%) underwent a PET study. This technique 
identified additional prostate bed foci of disease in 
4 patients (16%; 1.8% of all pts who had an MRI) 
and nodal disease only in 5 patients (20%; 2.4% 
of all pts who had an MRI). We compared clinical 
outcomes between the group of patients with nega-
table 1. patient and primary disease characteristics
Characteristic Patients
Gleason
6 (3 + 3)
7 (3 + 4)
7 (4 + 3)
8 (3 + 5)
8 (4 + 4)
9 (4 + 5)























































Undetectable in 81 (29.2%)
Median time rp — relapse 30 months (1–184)
Median time relapse — srT 10 months (0.2–136)
aDT — androgen deprivation therapy; rp — radical prostatectomy;  
srT — salvage radiotherapy
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tive MRI who had undergone PET/CT (whether 
positive or negative) with those who had not had 
a PET/CT done. A non-significant trend towards 
worse BC-RFS was observed for patients who had 
undergone a PET study (p = 0.317), as well as a sig-
nificantly worse C-RFS and HT-FS (p = 0.030 and 
p = 0.022, respectively). However, this group had 
a significantly higher median pre-sRT PSA value 
(0.82 vs. 0.47 ng/mL, p = 0.027) and a non-signifi-
cant trend towards more frequent lymphovascular 
invasion (36% vs. 20%, p = 0.200) and negative 
margins (74% vs. 64%, p = 0.377). Advanced pT 
stages were balanced between the two groups.
Conversely, out of 35 patients with negative 
PET/CT, 22 underwent MRI studies. Of these, 
prostate bed foci of relapse was identified in 6 
(27.3%; 8.3% of all pts who had a PET/CT), and 
no additional nodal disease was diagnosed. The 
outcome analysis also identified worse BC-RFS 
(p = 0.043), C-RFS (p = 0.361) and HT-FS 
(p = 0.057) for the PET-negative group who had 
undergone further imaging with MRI, whether 
positive or negative, in comparison with those 
who had not. Likewise, there was a trend towards 
more frequent lymphovascular invasion (36% vs. 
11%, p = 0.307) and negative margins (86% vs. 
54%, p = 0.111) in this group.
The positive MRI group had a significantly high-
er median pre-sRT in comparison with the nega-
tive MRI group (0.76 vs. 0.51 ng/mL, p = 0.001), 
with non-significant differences in the frequency 
of negative margins (71% vs. 66%, p = 0.783), lym-
phovascular invasion (83% vs. 77%, p = 0.435) and 
more advanced pT stages (pT3a or b in 45% vs. 36%, 
p = 0.426). On the other hand, patients with a positive 
PET/CT study also had higher median pre-sRT values 
than the negative group (2.51 ng/mL vs. 0.76 ng/mL, 
p < 0.001), and a non-significant trend was found 
towards less frequent negative margins (74% vs. 61%, 
p = 0.244), as well as more frequent lymphovascular 
invasion (45% vs. 20%, p = 0.062) and advanced pT 
stages (pT3a or b in 50% vs. 31%, p = 0.374).
Distant bone metastases were excluded by bone 
scintigraphy in 167 patients (60.3%), and 28 pa-
MRI (n = 206)
PET/CT in 25 pts
PET/CT (n = 72) 
MRI in 22 pts
Positive — 92 (44.7%)
Negative — 114
(55.3%)
Nodal — 4 (1.9%)
All w/ local disease
Local — 4 (16%)





Nodal — 13 (18.1%)
1 w/ local disease
Local — 25 (34.7%)





Local — 92 (44.7%)
Figure 1. restaging imaging modalities before salvage radiotherapy (srT). MrI — magnetic resonance imaging; 
peT/cT — positron emission tomography/computed tomography
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tients (10.1%) were referenced to our department 
and underwent prostate bed sRT without prior re-
staging imaging studies.
srT characteristics
All patients received prostate bed irradiation, 
to doses ≥ 66 Gy in 79.4% (Tab. 2). The lowest 
prescription dose was 60 Gy and the highest was 
74 Gy. A boost to prostate bed foci of disease was 
administered in 92 patients (33.2%), to a total 
dose ≥ 72 Gy in 54.4% (with a simultaneous in-
tegrated boost technique in 84 patients, 91.3%). 
This group included most patients whose pros-
tate bed dose was < 66 Gy, as a way to escalate 
dose (44 pts, 77.2%). Pelvic irradiation was ad-
ditionally performed in 27 patients (9.7%), most 
to 45Gy (74.1%). A nodal boost was delivered in 
11 patients, more frequently to total doses of 60Gy 
(45.5%) or 70Gy (36.4%). Most were planned with 
an IMRT technique (86.3%), and the remaining 
with VMAT. Androgen deprivation therapy (ADT) 
was prescribed for 18 patients (6.5%), a median of 
29.4 months (range: 1.4–83.5).
Treatment outcomes, patterns of failure
Outcome analysis was performed for 264 pa-
tients, for whom follow-up information was 
available. Median follow-up was 35.6 months 
(4.5–86.8). At 3 years, BC-RFS was 61.4%, C-RFS 
was 81.3%, HT-FS was 79.9% and OS was 96.6%. 
At the end of follow-up, a biochemical failure had 
been diagnosed in 101 patients (38.3%), and 52 
patients had had a clinical relapse (19.7%). Out 
of 48 patients who suffered clinical relapse during 
follow-up (18.2%), the most common location was 
the regional lymph nodes alone (n = 23; 47.9%), 
followed by distant relapse (n = 12; 25.0%), region-
al nodal and distant relapse (n = 8; 16.7%), prostate 
bed alone (n = 3; 6.2%), prostate bed and regional 
lymph nodes (n = 1; 2.1%) and prostate bed, nodal 
and distant relapse (n = 1; 2.1%).  Four of the 23 
patients who suffered regional nodal-only relapse 
had not been imagiologically evaluated prior to 
sRT (17.4%, whose clinical relapse was diagnosed 
a median of 40 months post-sRT). Surgical mar-
gins had been negative in most of these patients 
(n = 18; 81.8%).
Thirty-four patients showed PSA persistence on 
the first measurement after sRT (12.9%) — their 
median pre-sRT PSA was non-significantly high-
er than that of patients without PSA persistence 
(0.75 vs. 0.58 ng/mL, p = 0.193).
In opposition, undetectable PSA was achieved in 
75 patients (28.4%), a median of 11.2 months after 
sRT (from 2 to 52 months). Median pre-sRT PSA 
was significantly lower in this population, com-
pared with the group who did not achieve unde-
tectable PSA (0.42 vs. 0.65 ng/mL, p < 0.01). In 
the undetectable PSA group, only 5 patients later 
suffered a biochemical relapse (6.7%) and 2 had 
a clinical relapse (2.7%). Among the group that did 
not achieve undetectable PSA, biochemical relapse 
was significantly more common (48.1%, p < 0.01), 
as well as clinical relapse (24.3%, p < 0.01).
Impact of disease characteristics  
on the outcome
On MVA retaining relevant variables previously 
studied in UVA (Tab. 3), we observed that BC-RFS 
was negatively influenced by lymphovascular inva-
sion (p = 0.029), advanced pT stages (p = 0.002) 
and negative surgical margin after RP (p < 0.001). 
HT-FS was also negatively impacted by these 3 fac-
tors (p =  0.001, p = 0.029 and p = 0.002, respec-
tively). The presence of lymphovascular invasion 
and negative surgical margins also worsened C-RFS 
(p = 0.009 and p = 0.015, respectively), but OS was 
not affected by any of these.
Impact of srT timing
sRT was started with PSA > 0.5 ng/mL in 144 pa-
tients who had follow-up data (54.4% — group B). 
Group B had a higher prevalence of pT3a or b tu-
mors (51.8 vs. 32.7%, p = 0.001), but the remaining 
characteristics that had been tested were balanced 
table 2. salvage radiotherapy doses and volumes































*Including 44 out of 57 pts who received < 66Gy to the prostate bed (77.2%)
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between the two (grade group, surgical margins, 
perineural invasion, lymphovascular invasion, ini-
tial PSA value, post-RP undetectable PSA, adjuvant 
ADT). Median time from relapse to start of sRT was 
also longer in group B than group A (13.1 vs. 5.5 
months, p < 0.001).
BC-RFS was significantly superior on group 
A (67.8 vs. 56.0% at 3 years, p = 0.011), as well as 
HT-FS (86.6 vs. 74.6% at 3 years, p = 0.001). No 
significant differences were found on C-RFS (82.3 
vs. 80.6% at 3 years, p = 0.324) or OS (96.8 vs. 96.5% 
at 3 years, p = 0.479) (Fig. 2).
Discussion
In our study, we sought to determine the most 
significant factors influencing outcomes after sRT. 
Upon biochemical relapse after RP, the use of either 
MRI or PET/CT for restaging is recommended by 
the EUA guidelines in the case when findings al-
ter treatment decisions. [9] MRI is recommended 
by ESUR for pelvic evaluation in patients with low 
PSA levels (0.2–2 ng/mL), with detection rates that 
vary from 24% to 91% [10] Conversely, on a sur-
vey by Panje et al. all the centers recommended 
18F-choline or 68Ga-PSMA PET/CT for restaging, 
and it has been reported to change management in 
55% patients [11, 12]. According to a meta-analysis, 
although with a suboptimal sensitivity, 18F-choline 
PET/CT is more accurate for lymph node detection 
than MRI [13]. In addition, 68Ga-PSMA PET/CT 
shows excellent specificity and positive predictive 
values for lymph node detection, with per-patient 
sensitivity ranging from 33.3 to 100% [14]. In order 
to improve the detection of pelvic relapses, some au-
thors have proposed combining the two techniques 
[10]. Although there may be a bias, we found that 
these techniques complemented each other in a rel-
evant percentage of cases (with PET/CT identifying 
additional foci of disease in 36% of patients with 
negative MRI who underwent PET/CT, and MRI 
diagnosing prostate bed relapse in 27.3% of patients 
with negative PET/CT who underwent MRI). There 
is relevant heterogeneity in studies evaluating this 
topic, but some series have suggested that these im-
aging studies have a potential impact on outcomes 
(with better treatment response in PET-negative 
patients or in those with prostate bed foci [15]; and 
table 3. Multivariate analysis for each outcome
Outcome Variable p-value HR (95% CI)
Bc-rFs
Lymphovascular invasion 0.029 1.956 (1.071–3.573)























Lymphovascular invasion 0.001 3.697 (1.726–7.918)























Lymphovascular invasion 0.009 2.698 (1.287–5.655)








Bc-rFs — biochemical relapse-free survival; hT-Fs — additional hormone therapy-free survival; c-rFs — clinical relapse-free survival 
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an improvement in prognostication when MRI is 
analysed together with other clinical and pathologi-
cal variables after sRT [16]) and treatment decisions 
(with 63% nodal relapses identified by 68Ga-PSMA 
PET/CT being located on the pelvis and lumboaor-
tic region and 95% of them being amenable to sRT 
[17–19]; and the possibility of MRI-guided adaptive 
radiotherapy or boosts, reported by several authors 
[10]). Although we found worse outcomes for pa-
tients with negative MRI who had undergone ad-
ditional PET/CT, the higher pre-sRT PSA value and 
trend towards more frequent negative prognosis fac-
tors in this group suggests these differences may be 
explained by an attempt to pursue further imaging 
studies in perceived worse prognosis patients, creat-
ing a selection bias. The same was observed for the 
negative-PET/CT group who underwent MRI [21].
In our cohort, few patients received salvage 
ADT. In fact, results from RTOG 9601 (24 months 
bicalutamide during and after sRT) [22] and 
GETUG-AFU 16 (goserelin on the first day of sRT 
and at 3 months) [23] have since supported the use 
of concomitant ADT, which is now recommended 
by ASTRO/AUA guidelines. [24] Since this cohort 
was treated before long follow-up results from 
these randomized clinical trials were made avail-
able, ADT was not standard in our Institution and, 
therefore, PSA follow-up was included from the 
conclusion of sRT in most patients.
We observed a 3-year BC-RFS of 61.4%, which 
is comparable to that reported in a systematic re-
view, of 57–64% [25]. Overall, clinical recurrence 
was noted in 18.2% patients, predominantly in the 
regional lymph nodes alone (in 47.9% clinically 
relapsed patients). Of these, 17.4% had not been 
radiologically staged by MRI or PET/CT prior to 
sRT. In spite of a relatively long median time to 
clinical relapse (40 months), this emphasizes the 
importance of adequate systematic imaging studies 
prior to sRT. Our predominant pattern of failure 
and its crude rate (23 in 264 patients, 8.9%) are in 
agreement with data from Brand et al. (who report 
Figure 2. survival analysis comparison between Group a (pre-srT psa ≤ 0.5 ng/mL, black solid line) and Group B 
(pre-srT psa > 0.5 ng/mL, red dotted line); srT — salvage radiotherapy; psa — prostate-specific antigen
Time [months] Time [months]
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crude nodal-only relapse rates of 11% with a 7 year 
follow-up), especially given that our follow-up time 
is shorter [26].
Patients with positive margins after RP have been 
reported to suffer biochemical recurrence and un-
dergo RT more frequently [27, 28]. In these cases, 
it is more likely that the focus of relapse is on the 
prostate bed. Since all of our patients received sRT 
to a prostate bed volume, it is then probable that 
they received sRT to the site of relapse, whereas foci 
of disease on negative margin patients could be oc-
cult on imaging studies and, therefore, not targeted. 
Otherwise, the residual disease could have driven 
biochemical relapse for positive margin patients, 
whereas the negative margin population could cor-
respond to more intrinsically aggressive tumors. 
These are hypothesis that could explain the ob-
served “protective” influence of a positive margin on 
outcomes after sRT in this population. This finding 
was also observed in several retrospective studies, 
such as those by Jackson, Ervandian, Galla, Fossati 
and Goenka who noted better outcomes in patients 
with positive margins after sRT [29, 30, 31, 32].
According to several retrospective studies, 
a higher pathological T stage is associated with 
poorer biochemical relapse-free survival, which our 
data corroborates. Some have also correlated higher 
stages with lower metastasis-free survival and pros-
tate cancer-specific survival [29, 31].
Lymphovascular invasion has also been linked 
with poor prognosis after sRT. Worse biochemical 
failure-free survival after sRT has been reported 
in several retrospective series. Jeong et al. also de-
scribed significantly worse clinical failure-free sur-
vival and cancer-specific survival for patients with 
lymphovascular invasion [33].
We observed more favourable BC-RFS and 
HT-FS for patients who had undergone early 
sRT (which was defined as sRT with a PSA ≤ 0.5 
ng/mL). No significant differences were observed 
on C-RFS and OS, possibly due to a low number of 
events (although a trend for more favourable C-RFS 
and OS was observed for Group A). The defini-
tion of “early sRT” is widely variable, including the 
one used in ongoing randomized trials comparing 
adjuvant radiotherapy with early sRT: on RADI-
CALS-RT, treatment is initiated when biochemical 
failure is diagnosed (defined by three consecutive 
rises in PSA, or two consecutive rises with a final 
PSA > 0.1 ng/mL) [3]; on RAVES, sRT is triggered 
by PSA ≥ 0.2 ng/mL [4]. Nevertheless, the benefit 
of early rather than late sRT has been broadly de-
scribed in the literature, with Stish et al. reporting 
a significant increase in biochemical recurrence, 
distant metastasis, cancer specific mortality and 
all-cause mortality with each pre-sRT PSA dou-
bling. Additionally, they reported a significantly 
lower incidence of biochemical relapse, distant me-
tastasis and cancer specific mortality when pre-sRT 
PSA was ≤ 0.5 ng/mL [34].
Driven by its retrospective nature, our study has 
several limitations, including possible missing data. 
The fact that patients later underwent different sur-
veillance protocols (according to their attending 
physician) may also limit data interpretation, since 
the periodicity of PSA dosing, clinical evaluation 
and the threshold for requesting additional imag-
ing studies may have varied. In addition, criteria for 
requesting imaging studies to characterize initial 
relapse before sRT varied, which may be respon-
sible for some bias regarding the analysis of how 
MRI and PET/CT performed in such setting. The 
median follow-up time (35.6 months) is also short 
for prostate cancer.
conclusion
We highlighted the importance of adequate re-
staging prior to sRT, with occult disease in MRI hav-
ing been identified on PET/CT, and vice-versa. The 
primary pattern of relapse in our cohort was in the 
regional lymph nodes, with similar outcomes to those 
described in the literature. Prognosis was negatively 
influenced by the presence of lymphovascular inva-
sion, higher pathological T-stages and negative mar-
gins, but an early start of sRT (namely with PSA ≤ 0.5 
ng/mL) was a predictor of better BC-RFS and HT-FS. 
Therefore, a prompt diagnosis of relapse and restag-
ing, especially in patients with adverse prognostic 
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